Please login to the form below

Not currently logged in
Email:
Password:

Anti-BCMA

This page shows the latest Anti-BCMA news and features for those working in and with pharma, biotech and healthcare.

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

In June, AbbVie exercised a right to acquire TeneoOne – a Teneobio affiliate – which includes adding an anti-CD3/BCMA bispecific TNB-383B candidate for the treatment of relapsed or refractory multiple ... These three affiliates are developing an

Latest news

  • Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

    Pfizer has paused enrolment for a phase 2 trial evaluating its anti-BCMA bispecific antibody elranatamab, following three cases of peripheral neuropathy in an ongoing phase 1 study. ... The company announced the pause for the MagnetisMM-3 trial, which is

  • GSK’s anti-BCMA drug leads crowded CHMP recommendations GSK’s anti-BCMA drug leads crowded CHMP recommendations

    The anti-BCMA therapy has received a positive opinion for the treatment of relapsed and refractory multiple myeloma in patients who no longer respond to treatment with an immunomodulatory agent, a ... The positive recommendation from the CHMP means that

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for multiple myeloma. ... However, on that front there are a number of rivals already developing anti-BCMA therapeutics,

  • FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

    If approved will become first BCMA targeting drug for myeloma. GlaxoSmithKline looks set to win the race to bring a BCMA-targeting drug to market for multiple myeloma, after gaining a ... This includes belantamab mafodotin, which is a particularly

  • GSK files anti-BCMA drug for myeloma after second trial win GSK files anti-BCMA drug for myeloma after second trial win

    GSK reckons it has the advantage of a solid lead over the other anti-BCMA drug therapies, while GSK2857916 also sidesteps the serious and sometimes life-threatening toxicity that is associated ... and an anti-CD38 antibody – and will try to move the

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...